Clinical Trials Logo

Cerebellar Ataxia clinical trials

View clinical trials related to Cerebellar Ataxia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05992207 Completed - Cerebellar Ataxia Clinical Trials

Utilization of Motor Imagery Training for Improvement of Balance of Ataxic Children After Medulloblastoma Resection

Start date: January 21, 2023
Phase: N/A
Study type: Interventional

Background: after resection of medulloblastoma in children they suffer from signs and symptoms of ataxia which impedes their activities of daily living. purpose: to investigate the effect motor imagery training on balance, severity of ataxia and gait parameters on children after resection of medulloblastoma. Methods: Fifty children surfing from cerebellar ataxia after medulloblastoma resection were selected from tumors hospital of Cairo University, their age ranged from seven to nine years old, they were randomly assigned into two matched control and study groups. The control groups received the selected physical therapy program while, the study group received motor imaginary training in addition to the selected physical therapy program. Both groups were evaluated by ataxic rating scale, pediatric berg balance scale and kinematic gait analysis by kinovea software.

NCT ID: NCT05951010 Completed - Clinical trials for Spinocerebellar Ataxias

Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia 38

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

Spinocerebellar ataxia 38 (SCA 38) is a very rare autosomal dominant inherited disorder caused by a mutation in ELOV5 gene, specifically expressed in cerebellar Purkinje cells, encoding an enzyme involved in the synthesis of fatty acids. The present study aimed to assess the effect of cerebellar anodal transcranial direct current stimulation (tDCS) administered employing deltoid (CD-tDCS) and spinal (CS-tDCS) cathodal montage. Clinical evaluation was performed at baseline (T0), after 15 sessions of tDCS (T1) and after one month of follow-up (T2).

NCT ID: NCT05680571 Completed - Parkinson Disease Clinical Trials

Validation of Bulbicam for Parkinson- and Ataxia-patients

Start date: December 19, 2022
Phase:
Study type: Observational

Aim is to investigate repeatability and stability of four Neurological-related Bulbicam tests in patients suffering Parkinson (PD),Ataxia (AT) and matched healthy control (HC). Study population The study consists of the patients suffering from PD or AT and HV of both genders above 18 years of age without any eye- or neurological disorder. Bulbicam will be used in the study and five tests will be performed The study will be performed as a controlled, open and non-randomized, stratified observational single center. The stratification factors will be pathology (PD&AT) and internal classifications. ed. The main variables will be the variables recorded at the four Bulbicam tests and the standard neuro-ophthalmological variables included for PD and AT Participants, who fulfil the inclusion criteria; do not meet any of the exclusion criteria and willing to give informed consent to participate will receive an appointment for starting the study. During the first day of the study, the included patients will undergo a neuro-ophthalmological examination by a neurologist. Additionally, Bulbicam examination will be performed twice with a rest period of one hour between each registration. The healthy controls will only undergo a standard examination and twice BulbiCam examination. The controls will only participate one day. The patients will participate two more days with two Bulbicam examinations per day. Sample size: Sixteen PD-patients ,16 AT-patients and 32 HCs will be included in the study.

NCT ID: NCT05621200 Completed - Clinical trials for Multiple System Atrophy

Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia

SCAtACS
Start date: January 28, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the effects on motor and cognitive performance of transcranial alternating current stimulation (tACS) compared to transcranial direct current stimulation (tDCS) and placebo stimulation (sham) in patients with neurodegenerative ataxia to identify a possible rehabilitation protocol.

NCT ID: NCT05579691 Completed - Friedreich Ataxia Clinical Trials

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Start date: September 21, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) administration of CTI-1601 over 28 days in subjects with Friedreich's ataxia (FRDA).

NCT ID: NCT05573698 Completed - Friedreich Ataxia Clinical Trials

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

Start date: September 27, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of multiple doses of intravenous DT-216 in adult patients with Friedrich Ataxia.

NCT ID: NCT05479656 Completed - Clinical trials for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

A Rehabilitation Program to Increase Balance and Mobility in Ataxia of Charlevoix-Saguenay

Start date: May 13, 2019
Phase: N/A
Study type: Interventional

This exploratory study used a pre-post test design. The supervised rehabilitation program was performed three times a week for 8 weeks (two sessions at a rehabilitation gym and one pool session). Outcome measures included Ottawa sitting scale, 30-Second Chair Stand test, Berg Balance Scale, 10-Meter Walk Test, 6-minute Walk Test, modified Activities-specific Balance Confidence Scale and SARA scale. 10 participants will complete the training program. They will be evaluated at baseline, at week 4 (miway) and after the program.

NCT ID: NCT05471310 Completed - Clinical trials for Ataxia Telangiectasia

Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia

Start date: March 15, 2021
Phase:
Study type: Observational

Ataxia-telangiectasia (A-T) is a multisystem auto-somal recessive disorder linked to the A-T mutated gene (ATM) on chromosome 11q22-23, and characterized by progressive neural degeneration, immunodeficiency, and progressive ocular motor dysfunction. In previous studies, the quantitative description of the ocular motor deficits from clinical examination was limited to various defects in saccade and gaze control, dysmetric saccades, impairments of smooth pursuit, gaze holding, convergence, vestibular and optokinetic nystagmus slow phases, and cancellation of the vestibulo-ocular reflex. The aim of our research is to add existing findings with quantitative description of oculomotor patterns in A-T patients using videooculography (VOG).

NCT ID: NCT05436262 Completed - Cerebellar Ataxia Clinical Trials

Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia

Start date: March 14, 2023
Phase: N/A
Study type: Interventional

The aim of the research is to improve motor function in people with cerebellar ataxia by using neuroimaging methods and mental imagery to "exercise" motor networks in the brain. The relevance of this research to public health is that results have the potential to reduce motor deficits associated with cerebellar atrophy, thereby enhancing the quality of life and promoting independence.

NCT ID: NCT05436249 Completed - Healthy Clinical Trials

Use of Real-Time Functional Magnetic Resonance Imaging Neurofeedback to Improve Motor Function in Cerebellar Ataxia

fMRI
Start date: December 7, 2022
Phase: N/A
Study type: Interventional

This project will study the feasibility of motor rehabilitation in people with cerebellar ataxia using real-time functional magnetic resonance imaging neurofeedback (rt-fMRI NF) in conjunction with motor imagery. To do so, data will be collected from healthy adults in this protocol, to be compared with data from cerebellar ataxia participants.